发布: 2017年09月20日第7卷第18期 DOI: 10.21769/BioProtoc.2555 浏览次数: 7103
评审: Nicoletta CordaniAnonymous reviewer(s)
Abstract
Anthracyclines, such as doxorubicin and daunorubicin, are DNA damaging agents that autofluoresce and can be readily detected in cells. Herein, we developed suitable assays to quantify and localize daunorubicin in mammalian cells. These assays can be exploited to identify components that are involved in the uptake of anthracyclines.
Keywords: Influx transporters (流入转运蛋白)Background
The anthracyclines, such as doxorubicin and daunorubicin, act by damaging the DNA and are used for treating various types of cancers including acute myeloid leukemia. When cancer patients are given anthracyclines systemically, there are several factors limiting the amount of the drugs that reach the tumor sites (Chauncey, 2001; Deng et al., 2014; Riganti et al., 2015). In the tumor, the drug activity on the cancer cells is limited by poor drug uptake, excessive drug efflux as well as changes in the cellular targets. For several decades, it remains unclear how these DNA damaging agents enter cancer cells (Aouida et al., 2010; Cesar-Razquin et al., 2015; Zhang et al., 2015). To address this question, we developed three reliable in vitro assays to monitor daunorubicin accumulation into cells. Two of these assays are quantitative and required access to a Fluorescence-Activated Cell Sorting (FACS) caliber and a Fluoroskan instrumentation and the third is semi-quantitative using epifluorescence microscopy. Using these assays, we established that daunorubicin enter into cells in a time- and concentration-dependent manner and that each cell type showed a different rate of uptake, suggesting that an active process is involved in the uptake of anthracyclines (Andreev et al., 2016). We applied these assays and uncovered the organic cation transporter 1 (OCT1) as a key protein for the uptake of daunorubicin into the cells (Andreev et al., 2016). Modulating the level of OCT1 resulting in cells with altered uptake and sensitivity towards daunorubicin (Andreev et al., 2016). These assays provide hints that additional transporters exist to allow uptake of daunorubicin into the cells. We believe that these uptake assays can be exploited further to identify additional factors such as kinases (Tanaka et al., 2004; Ciarimboli and Schlatter, 2005; Zhou et al., 2005; Pelis et al., 2006; Filippo et al., 2011; Sprowl et al., 2016) that influence the rate of daunorubicin uptake. In this protocol, we describe three analyses to monitor the uptake of anthracyclines into cells.
Materials and Reagents
Equipment
Software
Procedure
文章信息
版权信息
© 2017 The Authors; exclusive licensee Bio-protocol LLC.
如何引用
Brosseau, N., Andreev, E. and Ramotar, D. (2017). Uptake Assays to Monitor Anthracyclines Entry into Mammalian Cells. Bio-protocol 7(18): e2555. DOI: 10.21769/BioProtoc.2555.
分类
癌症生物学 > 癌症生物化学 > 基因毒性
癌症生物学 > 基因组不稳定性及突变 > 癌症治疗
细胞生物学 > 细胞成像 > 荧光
您对这篇实验方法有问题吗?
在此处发布您的问题,我们将邀请本文作者来回答。同时,我们会将您的问题发布到Bio-protocol Exchange,以便寻求社区成员的帮助。
提问指南
+ 问题描述
写下详细的问题描述,包括所有有助于他人回答您问题的信息(例如实验过程、条件和相关图像等)。
Share
Bluesky
X
Copy link